-
Product Insights
Southern Current Solar PV Park
Southern Current Solar PV Park is a solar PV project located in South Carolina, United States. The project is owned by John Hancock Life Insurance Co; Pine Gate Renewables LLC and was developed by Cypress Creek Solutions; Pine Gate Renewables LLC. The project came online in 2017. Empower your strategies with our Southern Current Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be...
-
Sector Analysis
NewUnited Kingdom (UK) Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to 2028
United Kingdom (UK) Construction Market Report Overview The UK construction market size was $509.3 billion in 2023. The market will achieve an AAGR of more than 2% during 2025-2028 supported by investments in renewable energy, industrial, and infrastructure projects. UK Construction Market Outlook, 2023-2028 ($ Billion) Buy the Full Report to Know More about the UK Construction Market Forecast Download a Free Report Sample The UK construction market research report gives a comprehensive understanding of project types and construction activities...
-
Sector Analysis
NewSouth Korea Source Tourism Insight by Domestic and Outbound Tourism, Key Destinations and Tourist Profiles, 2024 Update
GlobalData’s Tourism Source Market Insight: South Korea report provides a thorough insight into the South Korea's domestic and outbound tourism market. The report looks at the profiles of South Korean tourists and summarizes the key reasons that they travel. The report offers an in-depth analysis of traveler flows, spending patterns, main destination markets and current and future opportunities for tourism businesses seeking to tap into the South Korea's outbound travel market.
-
Product Insights
NewLikelihood of Approval Analysis for Pancreatic Tumor
Overview How likely is it that the drugs in Pancreatic Tumor will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pancreatic Tumor Overview Pancreatic cancer refers to the carcinoma arising from the...
-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Ulevostinag
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Ulevostinag report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: GSK plc’s Belrestotug
Empower your strategies with our Net Present Value Model: GSK plc's Belrestotug report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Anselamimab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Anselamimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.